# US 2012/0252733 A1 · Use of targeted nitroxide agents in bone healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252733 A1
- Document ID: US20120252733A1
- Status: Published application
- Kind: A1
- Application number: 13/320,999
- Filed: 2010-06-04
- Published: 2012-10-04
- Earliest claimed: 2009-06-05
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Inventors: Michael W. Epperly; Abhay Sudhir Gokhale; Joel S. Greenberger; Peter Wipf; Julianne Glowacki
- Web page: https://patentgrep.com/patent/US20120252733A1

## CPC

- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions and related methods useful for accelerating bone healing and growth. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity.

## Claims

### Claim 1

A method of accelerating bone healing, growth or repair in a subject, comprising administering to the subject prior to, during or after bone injury, damage or deficiency in the subject, a composition comprising an amount of a targeted nitroxide compound effective to accelerate bone repair in the subject, wherein the targeted nitroxide compound comprises a mitochondria targeting group and a nitroxide-containing group.
wherein the targeted nitroxide compound is chosen from one of:
a). a compound having the structure:
wherein X is one of
R1 and R2 are C1-C6 straight or branched-chain alkyl, or a C1-C6 straight or branched-chain alkyl further comprising a phenyl (C6H5) group, that is unsubstituted or is methyl-, hydroxyl- or fluoro-substituted, R4 is hydrogen, C1-C6 straight or branched-chain alkyl, or a C1-C6 straight or branched-chain alkyl further comprising a phenyl (C6H5) group, that is unsubstituted or is methyl-, hydroxyl- or fluoro-substituted; R3 is —NH—R5, —O—R5 or —CH2—R5, and R5 is an —N—O., —N—OH or N═O containing group; R is —C(O)—R6 or —C(O)O—R6, and R6 is C1-C6 straight or branched-chain alkyl or C1-C6 straight or branched-chain alkyl further comprising one or more phenyl (—C6H5) groups that are independently unubstituted, or methyl-, ethyl-, hydroxyl- or fluoro-substituted, and wherein the compound is not XJB-5-208;
b). a compound having the structure R1—R2—R3 in which R1 and R3 are the same or different and have the structure —R4—R5, in which R4 is a mitochondria targeting group and R5 is —NH—R6, —O—R6 or —CH2—R6, wherein R6 is an —N—O., —N—OH or N═O containing group and R4 and R5 for each of R1 and R3 may be the same or different; and R2 is a linker; and
c. from 2-10 consecutive amino acids of a gramicidin S polypeptide attached to a nitroxide-containing group.

### Claim 2 (depends on 1)

The method of claim 1, the compound having the structure:
in which R1 and R3 are, independently, C1-C6 straight or branched-chain alkyl, or C1-C6 straight or branched-chain alkyl including a phenyl (C6H5) group that is unsubstituted, methyl-, hydroxyl- or fluoro-substituted; R2 is H, C1-C6 straight or branched-chain alkyl, or C1-C6 straight or branched-chain alkyl including a phenyl (C6H5) group that is unsubstituted, methyl-, hydroxyl- or fluoro-substituted; R4 is an —N—O., —N—OH or N═O containing group; R is —C(O)—R5, —C(O)O—R5 or diphenylphosphate, and R5 is C1-C6 straight or branched-chain alkyl, or C1-C6 straight or branched-chain alkyl including a phenyl (C6H5) group that is unsubstituted, methyl-, hydroxyl- or fluoro-substituted.

### Claim 3 (depends on 2)

The method of claim 2, in which R5 is Boc or Cbz.

### Claim 4 (depends on 2)

The method of claim 2, in which R1, R2 and R3 independently are methyl, ethyl, propyl, 2-propyl, butyl, t-butyl, pentyl, hexyl, benzyl, hydroxybenzyl, phenyl and hydroxyphenyl.

### Claim 5 (depends on 2)

The method of claim 2, in which R4 is 2,2,6,6-Tetramethyl-4-piperidine 1-oxyl.

### Claim 6 (depends on 2)

The method of claim 2, having a structure chosen from:
wherein Ac is acetyl.

### Claim 7 (depends on 2)

The method of claim 2, wherein the compound if one of JP4-039, JP4-049, JED-E71-58 and JED-E71-37.

### Claim 8 (depends on 1)

The method of claim 1, in which the targeted nitroxide compound is a compound having the structure R1—R2—R3 in which R1 and R3 are the same or different and have the structure —R4—R5, in which R4 is a mitochondria targeting group and R5 is —NH—R6, —O—R6 or —CH2—R6, wherein R6 is an —N—O., —N—OH or N═O containing group and R4 and R5 for each of R1 and R3 may be the same or different; and R2 is a linker.

### Claim 9 (depends on 8)

The method of claim 8, wherein R1 and R2 are the same.

### Claim 10 (depends on 8)

The compound of claim 8, wherein R6 for one or both of R1 and R2 is 2,2,6,6-Tetramethyl-4-piperidine 1-oxyl.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of claim 8, in which R1 and R3 have any structure depicted in claims 1-19.

### Claim 12 (depends on 8)

The method of claim 8, in which the compound is one of JED-E71-58 and JED-E71-37

### Claim 13 (depends on 8)

The method of claim 8, in which R4, independently for each of R1 and R3 comprises a hemigramicidin derivative comprising a β-turn and TEMPO.

### Claim 14 (depends on 13)

The method of claim 13, in which R1 and R3, independently are chosen from XJB-5-131 and XJB-5-125.

### Claim 15 (depends on 8)

The method of claim 8, in which R2 comprises a linear or branched saturated C4-C20 alkyl.

### Claim 16 (depends on 15)

The method of claim 15, in which R2 has the structure:
in which n is 4-18.

### Claim 17 (depends on 16)

The method of claim 16, in which n is 10.

### Claim 18 (depends on 1)

The method of claim 1, in which the amount effective to accelerate bone repair in the subject ranges from 0.1 to 100 mg/Kg in the subject.

### Claim 19 (depends on 18)

The method of claim 18, in which the amount effective to accelerate bone repair in the subject ranges from 1 to 100 mg/Kg in the subject.

### Claim 20 (depends on 1)

The method of claim 1, in which the compound is chosen from one or more of XJB-5-133, XJB-5-208, XJB-2-300, XJB-2-70, XJB-5-131, XJB-5-125, XJB-5-197, XJB-7-53, XJB-7-55, and XJB-7-75.

### Claim 21 (depends on 1)

The method of claim 1, wherein the compound comprises a hemigramicidin attached to a nitroxide-containing group.

### Claim 22 (depends on 1)

The method of claim 1 in which the subject has low bone density.

### Claim 23 (depends on 22)

The method of claim 22, in which the patient has osteoarthritis.

### Claim 24 (depends on 1)

The method of claim 1, in which the subject has not been exposed to 10 Gy or more of radiation within about 24 hours of administration of the compound.

### Claim 25

Use of a compound chosen from one of:
a). a compound having the structure:
wherein X is one of
R1 and R2 are C1-C6 straight or branched-chain alkyl, or a C1-C6 straight or branched-chain alkyl further comprising a phenyl (C6H5) group, that is unsubstituted or is methyl-, hydroxyl- or fluoro-substituted, R4 is hydrogen, C1-C6 straight or branched-chain alkyl, or a C1-C6 straight or branched-chain alkyl further comprising a phenyl (C6H5) group, that is unsubstituted or is methyl-, hydroxyl- or fluoro-substituted; R3 is —NH—R5, —O—R5 or —CH2—R5, and R5 is an —N—O., —N—OH or N═O containing group; R is —C(O)—R6 or —C(O)O—R6, and R6 is C1-C6 straight or branched-chain alkyl or C1-C6 straight or branched-chain alkyl further comprising one or more phenyl (—C6H5) groups that are independently unubstituted, or methyl-, ethyl-, hydroxyl- or fluoro-substituted, and wherein the compound is not XJB-5-208;
b). a compound having the structure R1—R2—R3 in which R1 and R3 are the same or different and have the structure —R4—R5, in which R4 is a mitochondria targeting group and R5 is —NH—R6, —O—R6 or —CH2—R6, wherein R6 is an —N—O., —N—OH or N═O containing group and R4 and R5 for each of R1 and R3 may be the same or different; and R2 is a linker; and
c. from 2-10 consecutive amino acids of a gramicidin S polypeptide attached to a nitroxide-containing group for the preparation of a medicament for bone healing or for treating or preventing bone degeneration, optionally in osteoporosis.

### Claim 26 (depends on 25)

The use of claim 25 in which the compound is selected from the group consisting of one or more of XJB-5-133, XJB-5-208, XJB-2-300, XJB-2-70, XJB-5-131, XJB-5-125, XJB-5-197, XJB-7-53, XJB-7-55, XJB-7-75, JP4-039, JP4-049, JED-E71-58 and JED-E71-37

### Claim 27

The use of a compound chosen from one of:
a). a compound having the structure:
wherein X is one of
R1 and R2 are C1-C6 straight or branched-chain alkyl, or a C1-C6 straight or branched-chain alkyl further comprising a phenyl (C6H5) group, that is unsubstituted or is methyl-, hydroxyl- or fluoro-substituted, R4 is hydrogen, C1-C6 straight or branched-chain alkyl, or a C1-C6 straight or branched-chain alkyl further comprising a phenyl (C6H5) group, that is unsubstituted or is methyl-, hydroxyl- or fluoro-substituted; R3 is —NH—R5, —O—R5 or —CH2—R5, and R5 is an —N—O., —N—OH or N═O containing group; R is —C(O)—R6 or —C(O)O—R6, and R6 is C1-C6 straight or branched-chain alkyl or C1-C6 straight or branched-chain alkyl further comprising one or more phenyl (—C6H5) groups that are independently unubstituted, or methyl-, ethyl-, hydroxyl- or fluoro-substituted, and wherein the compound is not XJB-5-208;
b). a compound having the structure R1—R2—R3 in which R1 and R3 are the same or different and have the structure —R4—R5, in which R4 is a mitochondria targeting group and R5 is —NH—R6, —O—R6 or —CH2—R6, wherein R6 is an —N—O., —N—OH or N═O containing group and R4 and R5 for each of R1 and R3 may be the same or different; and R2 is a linker; and
c. from 2-10 consecutive amino acids of a gramicidin S polypeptide attached to a nitroxide-containing group for bone healing or for treating or preventing bone degeneration, optionally associated with osteoporosis.
